Please use this identifier to cite or link to this item:
Title in Portuguese: Pharmacotherapeutic follow-up of patients with Chagas disease using in use of benznidazole : drug-related problems and pharmaceutical interventions
Author: Correia, João Paulo Ramalho
Costa, Alanna Carla da
Rocha, Eduardo Arrais
Quidute, Ana Rosa Pinto
Cândido, Darlan da Silva
Ponciano, Ângela Maria de Souza
Fonteles, Marta Maria de França
Oliveira, Maria de Fátima
Keywords: Doença de Chagas
Chagas Disease
Issue Date: May-2017
Publisher: Revista da Sociedade Brasileira de Medicina Tropical
Citation: CORREIA, J. P. R. et al. Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole : drug-related problems and pharmaceutical interventions. Revista da Sociedade Brasileira de Medicina Tropical, v. 50, n. 3, p. 334-340, may./jun. 2017.
Abstract: Introduction : Benznidazole (BNZ) is a drug available for the etiological treatment of Chagas disease. However, this drug is toxic and has a limited effectiveness on the chronic phase of this disease, often leading to poor treatment adherence. Methods: This is a descriptive and exploratory study conducted at the Pharmaceutical Care Service for Chagas disease patients of the Federal University of Ceará. Drug-related problems (DRPs) and pharmaceutical interventions (PIs) were classified according to the Second Consensus of Granada. Results: The average age of patients with Chagas disease was 62 years, with the majority residing in the Ceará countryside (86.7%), and having low education levels (63.3% with elementary school education). Regarding family income, most patients belonged to a household that earned ≤1 -2 times the minimum wage per month. Approximately 73% of these patients complied with the BNZ treatment, and nearly 7% underwent therapy interruption after medical evaluation. A total of 189 DRPs were identified, of which 51.9 % (n=98) were classified as potential, and 48.1% (n=91) as actual. The most frequent DRPs were related to safety (qualitative safety; n=70; 37%), necessity (non-adherence; n=52; 27.5%), and effectiveness (qualitative effectiveness/non-optimal drug selection; n=45; 23.8%). Among the 216 PIs conducted, the majority were related to patient education (n=168; 77.8%) and pharmacological strategy (n=42; 19.4%). Conclusions: This study indicates the need for pharmacotherapeutic monitoring in patients with Chagas because of the high number of therapeutic interventions, DRPs (approximately 3 DRPs/patient), BNZ adherence, and polypharmacy.
metadata.dc.type: Artigo de Periódico
ISSN: Print version 0037-8682
On-line version 1678-9849
Appears in Collections:DFAR - Artigos publicados em revistas científicas

Files in This Item:
File Description SizeFormat 
2017_art_jprcorreia.pdf867,48 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.